Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
letter
. 2020 May 25;395(10239):1759–1760. doi: 10.1016/S0140-6736(20)30749-2

Caution against corticosteroid-based COVID-19 treatment

Chong Tang a, Yichuan Wang a, Houshan Lv b, Zhenpeng Guan a, Jin Gu c,d
PMCID: PMC7247780  PMID: 32464115

In December, 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, Hubei province, China, and COVID-19 has become a threat to global public health.1

Use of corticosteroid-based therapy to reduce inflammatory-induced lung injury has been described for patients with severe COVID-19,2, 3 similar to the use of corticosteroids to treat severe acute respiratory syndrome (SARS) during the SARS outbreak in 2003.4 However, improper use of systemic corticosteroids can increase the risk of osteonecrosis of the femoral head (ONFH).

In a retrospective study of 539 patients with SARS who received corticosteroid therapy,5 the incidence of steroid-induced ONFH was 24%, and increased incidence of steroid-induced ONFH was associated with total corticosteroid dose and the use of more than one type of corticosteroid. Improper or delayed treatment of steroid-induced ONFH can cause hip pain, claudication, and even disability of the lower limbs.

Overall, we call for caution in the use of corticosteroids for COVID-19 and do not recommend this as a routine treatment. To prevent steroidinduced ONFH, corticosteroids should be considered only for patients undergoing septic shock, or in critical cases.6, 7 Corticosteroids should be minimised in dose and duration, and the use of multiple types should be avoided. We believe that bisphosphonates and vitamin E should be prescribed to patients who are undergoing corticosteroid treatment; anticoagulants, vasodilators, and traditional Chinese medicine could also be considered.8, 9, 10 Close follow-up should be conducted after discharged, with MRI as the best option for early detection of ONFH. Physical therapy and combined pharmacotherapy have been recommended for patients with early-stage steroid-induced ONFH.11

Acknowledgments

We declare no competing interests.

References

  • 1.WHO Coronavirus disease (COVID-19) situation report - 119. May 18, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200518-covid-19-sitrep-119.pdf?sfvrsn=4bd9de25_4
  • 2.Huang C, Wang Y, Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chen N, Zhou M, Dong X. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chen RC, Tang XP, Tan SY. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129:1441–1452. doi: 10.1378/chest.129.6.1441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Guo KJ, Zhao FC, Guo Y, Li FL, Zhu L, Zheng W. The influence of age, gender and treatment with steroids on the incidence of osteonecrosis of the femoral head during the management of severe acute respiratory syndrome: a retrospective study. Bone Joint J. 2014;96-B:259–262. doi: 10.1302/0301-620X.96B2.31935. [DOI] [PubMed] [Google Scholar]
  • 6.Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. doi: 10.1016/S0140-6736(20)30317-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683–684. doi: 10.1016/S0140-6736(20)30361-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005;87:2155–2159. doi: 10.2106/JBJS.D.02959. [DOI] [PubMed] [Google Scholar]
  • 9.Jia YB, Jiang DM, Ren YZ, Liang ZH, Zhao ZQ, Wang YX. Inhibitory effects of vitamin E on osteocyte apoptosis and DNA oxidative damage in bone marrow hemopoietic cells at early stage of steroid-induced femoral head necrosis. Mol Med Rep. 2017;15:1585–1592. doi: 10.3892/mmr.2017.6160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Liu LH, Zhang QY, Sun W, Li ZR, Gao FQ. Corticosteroid-induced osteonecrosis of the femoral head: detection, diagnosis, and treatment in earlier stages. Chin Med J (Engl) 2017;130:2601–2607. doi: 10.4103/0366-6999.217094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wang W, Zhang N, Guo W, Gao F. Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteen year follow-up. Int Orthop. 2018;42:1551–1556. doi: 10.1007/s00264-018-3907-x. [DOI] [PubMed] [Google Scholar]

Articles from Lancet (London, England) are provided here courtesy of Elsevier

RESOURCES